Bavarian Nordic AS operates in the Commercial physical research sector. Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines within biodefence, cancer and infectious diseases therapeutic areas. The Company operates within two segments: Cancer Vaccines and Infectious Disease. The Cancer Vaccines' pipeline is focused on therapeutic vaccines and includes two projects in prostate cancer, PROSTVAC (Phase 2) and MVA-BN PRO (Phase 1/2), and one project in breast cancer, MVA-BN HER2 (Phase 1/2). The Infectious Disease's pipeline is focused on prophylactic vaccines and includes a smallpox vaccine candidate, IMVAMUNE (Phase 2); an anthrax vaccine candidate, MVA-BN Anthrax (Preclinical); an RSV vaccine candidate, MVA-BN RSV (Preclinical), and a HIV vaccine candidate, MVA-BN HIV multiantigen (Phase 1/2). Bavarian Nordic A/S has research centers in Mountain View in the United States and Martinsried in Germany, and manufacturing facilities in Kvistgaard, Denmark, and Berlin, Germany. In our complete report available for purchase the company is compared to: Origio A/S, Fornix Biosciences and Genmab A/S.